Intuitive Surgical (NQ:ISRG)

391.95 -9.29 (-2.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intuitive Surgical

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026

January 27, 2026

NEW BRUNSWICK, N.J. — Johnson & Johnson (NYSE: JNJ) has officially closed the chapter on a year many analysts described as "transitional," reporting full-year 2025 earnings that met expectations while...

Via MarketMinute

Forget Tech Stocks: The Medical Device Maker That's Essential to AI Healthcare ↗

January 27, 2026

This company's surgical robots already use AI, and the future could be even more exciting.

Via The Motley Fool

Topics Artificial Intelligence

Da Vinci 5 Cleared for Cardiac Procedures

January 26, 2026

FDA 510(k) clearance expands da Vinci 5 indications to include certain cardiac procedures

From Intuitive Surgical, Inc.

Via GlobeNewswire

2 Growth Stocks to Stash and 1 We Question

January 25, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Via StockStory

Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors ↗

January 25, 2026

Via MarketBeat

3 Troubling Trends for Intuitive Surgical – and 1 Bright Spot ↗

January 24, 2026

This robotic surgical systems pioneer is dealing with a few issues, but its opportunities remain promising.

Via The Motley Fool

Topics Earnings Supply Chain

AI Bubble or Sustainable Growth? Here Are 2 Healthcare Companies Harnessing AI for the Long Term. ↗

January 23, 2026

Artificial intelligence may be all the rage in the technology sector, but it's also having a huge impact on healthcare.

Via The Motley Fool

Topics Artificial Intelligence

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

January 23, 2026

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Intuitive Surgical Just Proved the Growth Engine Still Runs ↗

January 23, 2026

Via MarketBeat

Intuitive Surgical Tops Expectations as Robotic Surgeries See Massive Surge ↗

January 23, 2026

Intuitive Surgical (NASDAQ: ISRG) reports in-line Q4 results, sets measured guidance for 2026, with an 18% revenue growth and $2.53 EPS.

Via Benzinga

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

ISRG Q4 Deep Dive: New Product Launches and International Growth Drive Results

January 23, 2026

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of...

Via StockStory

Topics World Trade

20 Million Patients Benefit from da Vinci Surgery Globally

January 23, 2026

Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive technologies

From Intuitive Surgical, Inc.

Via GlobeNewswire

Which S&P500 stocks are moving before the opening bell on Friday? ↗

January 23, 2026

Via Chartmill

This Often-Overlooked Growth Stock Just Reported An Amazing Quarter. Time to Buy Shares? ↗

January 22, 2026

This robotics company just put up another quarter of amazing growth, and the reasons to love the stock keep adding up.

Via The Motley Fool

Intuitive Surgical (ISRG) Earnings Transcript ↗

January 22, 2026

Intuitive Surgical (ISRG) Earnings Transcript

Via The Motley Fool

Topics World Trade

Intuitive Surgical Stock Climbs After Company Tops Q4 Earnings ↗

January 22, 2026

Intuitive Surgical Inc (NASDAQ:ISRG) reports financial results for the fourth quarter on Thursday. Here's a rundown of the report.

Via Benzinga

Intuitive Surgical (NASDAQ:ISRG) Delivers Impressive Q4 CY2025

January 22, 2026

Medical technology company Intuitive Surgical (NASDAQ:ISRG) announced better-than-expected revenue in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of $2.53 per...

Via StockStory

Intuitive Announces Fourth Quarter Earnings

January 22, 2026

From Intuitive Surgical, Inc.

Via GlobeNewswire

Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth

January 22, 2026

NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the...

Via MarketMinute

Topics Earnings Economy Intellectual Property

Where Will Intuitive Surgical Be in 5 Years? ↗

January 21, 2026

The bullish case for the stock remains strong.

Via The Motley Fool

Intuitive Surgical (ISRG) Q4 Earnings Report Preview: What To Look For

January 20, 2026

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting earnings this Thursday after the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

The Titan’s Balance: Johnson & Johnson Reaches Record Highs Amidst Legal Hurdles and Med-Tech Transformation

January 20, 2026

As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On...

Via MarketMinute

Topics Bankruptcy Lawsuit World Trade

2 Healthcare Names That Could Get a Big Boost From Earnings ↗

January 20, 2026

Via MarketBeat

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results....

Via MarketMinute

Topics Bankruptcy Earnings Economy

The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever ↗

January 19, 2026

All three of these healthcare giants are leaders in their niches.

Via The Motley Fool

Topics Artificial Intelligence

The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature

January 19, 2026

As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its...

Via Finterra

Topics Artificial Intelligence Bankruptcy Economy

My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling ↗

January 19, 2026

These stocks are definitely keepers.

Via The Motley Fool

Topics Artificial Intelligence

2 Large-Cap Stocks with Promising Prospects and 1 We Avoid

January 18, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

Topics Supply Chain

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.